Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

J.M. Fernández Gómez, Rosário Madero, Eduardo Solsona, +16

The Journal of Urology

Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

Urs E. Studer, Peter Whelan, Walter Albrecht, +8

Journal of Clinical Oncology

Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

J.M. Fernández Gómez, Eduardo Solsona, Miguel Unda, +16

European Urology

Prognostic FactorsUrologyBacillus Calmette-guérinUrologic Cancer EpidemiologyGenitourinary Cancer +7

Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer

J.A. Martínez‐Pin ̃eiro, N Flores, Santiago Isorna, +18

British Journal of Urology

A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

Antonio Ojea, José Luís Nogueira, Eduardo Solsona, +11

European Urology

UrologySurgical OncologyGenitourinary CancerMedicineVersus Mitomycin C +4

HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL

J A Martínez-Piñeiro, Luis Martínez‐Piñeiro, Eduardo Solsona, +13

The Journal of Urology

The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables

J.M. Fernández Gómez, Rosário Madero, Eduardo Solsona, +16

European Urology

External ValidationSurgical OncologyUrologyCancer EpidemiologyUrologic Cancer Epidemiology +12

Original Articles: Bladder Cancer: Neoadjuvant Cisplatin Chemotherapy Before Radical Cystectomy in Invasive Transitional Cell Carcinoma of the Bladder: A Prospective Randomized Phase III Study

J A Martínez-Piñeiro, M. González Martín, Fernando Arocena, +6

The Journal of Urology

Surgical OncologyAdjuvant ChemotherapySurgeryReconstructive UrologyGynecology Oncology +14

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

Urs E. Studer, Laurence Collette, Peter Whelan, +8

European Urology

UrologyEortc 30891Genitourinary CancerMedicineCancer Management +6

Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study.

Martínez-Piñeiro Ja, González Martín M, Fernando Arocena, +6

PubMed

Radical CystectomyUrologySurgical OncologyGenitourinary CancerMedicine +9